Wave Life Sciences, Duchenne muscular dystrophy
Wave Life Sciences’ stock soars 51% after biotech posts positive data from Duchenne muscular-dystrophy trial
Biotech reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne muscular dystrophy.
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced today that it has commenced an underwritten public offering of $175 million in aggregate of its ordinary shares,
Wave Life Sciences: Spiking On Strong DMD Data, But Not Fully De-Risked Yet
Wave Life Sciences stock surged over 50% today due to promising data from its Duchenne Muscular Dystrophy candidate WVE-N531. Explore more details here.
Buy Rating on Wave Life Sciences: Undervalued DMD Program and Promising Data Offer Investment Upside
Analyst Tiago Fauth from Wells Fargo maintained a Buy rating on Wave Life Sciences (WVE – Research Report) and keeping the price target
Wave Life Sciences Stock Surges On Promising Interim Data From Mid-Stage Study Of Muscular Disorder Drug
Wave Life Sciences Ltd. (NASDAQ:WVE) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping. DMD is a genetic disease that causes progressive muscle weakness and degeneration caused by a mutation in the dystrophin gene.
Wave Life Sciences gains on data for Duchenne therapy
Wave Life Sciences (NASDAQ:WVE) added ~8% premarket Tuesday after the RNA therapeutics company announced interim data from a Phase 2 trial for WVE-N531, an experimental therapy for a neuromuscular disorder known as Duchenne muscular dystrophy (DMD).
Wave Life And Capricor Surge Forward With Hope - Are These Stocks In Your Portfolio?
Duchenne muscular dystrophy, or DMD, is a severe genetic disorder, typically affecting males, and is characterized by progressive
Wave Life Sciences Shares Climb Premarket on Duchenne Study Data
Shares of Wave Life Sciences rose more than 10% in premarket trading Tuesday after the clinical-stage biotechnology company reported positive interim data from a mid-stage study of its WVE-N531 drug candidate in the neuromuscular genetic disease Duchenne muscular dystrophy.
Wave Life Sciences Ltd. (Nasdaq: WVE) Gains on Clinical Trial News
The stock is trading at $8.18, up $2.84, gaining 53.18% on volume of over 12.4 Million shares. The stock had a days' high of $8.33.
FierceBiotech13h
Wave surfs DMD success to regulators' doors, sending stock up
Wave’s result is in line with the data that supported accelerated approval of NS Pharma’s exon 53 DMD drug Viltepso. NS ...
ENDPOINTS NEWS11h
Wave rides new Phase 2 DMD da­ta as it sets sights on ac­cel­er­at­ed ap­proval
Wave Life Sciences said new Phase 2 biomarker data for its exon-skipping therapy are promising for certain patients with ...
BRIEF-Wave Life Sciences Says It Reduced Maximum Offering Amount To $0 & No Longer Intends To Sell Ordinary Shares Under Prospectus
WAVE LIFE SCIENCES- EFFECTIVE AS OF SEPT 24, REDUCED MAXIMUM OFFERING AMOUNT TO $0 & NO LONGER INTEND TO SELL ORDINARY SHARES UNDER PROSPECTUS Source text for Eikon: Further company coverage: ...
STAT14h
Metsera’s GLP-1 drug has potential for monthly dosing, new data show
Novo Nordisk CEO Lars Fruergaard Jørgensen will testify at a Senate hearing today about the prices of Ozempic and Wegovy.